We’ve written about Israeli company InspireMD most recently here with the news that the company’s embolic protection coronary stent study had successfully completed enrollment. Now the company has announced that its president and co-founder Asher Holzer, Ph.D., is retiring as president of the Company.
Dr. Holzer served as the CEO and founder of Adar Medical, from 2002 through 2004, an investment firm specializing in medical device startups. Within this capacity, he led investments in Cyber Stent, Vasculogix, NVR, and Theracoat. Dr. Holzer has held a wide variety of positions including; CEO, product line manager, division manager, and worldwide product manager at a number of companies including start ups, Kevex corporation, and Johnson & Johnson. In his role at Johnson & Johnson he served as worldwide product manager of the Carto SystemTM, taking the product from development to worldwide sales. Dr. Holzer earned his Ph.D. in Applied Physics from the Hebrew University. (1980) Dr. Holzer is the inventor of numerous patents.
Dr. Holzer will remain a director of InspireMD and will also provide the Company with consulting services for a period of six months. His replacement in the role of president has not yet been named.
About MGuard™ Coronary Stent
MGuard™ combines a coronary stent merged with an embolic protection specifically designed for acute MI patients. The embolic protection is comprised of an ultra-thin polymer micron net that wraps the stent. The MGuard™ stent seeks to provide outstanding and lifelong embolic protection, without affecting deliverability. MGuard™ is CE Mark approved.
Mesh-based protection is now recommended for use in the recent Guidelines of the Task force of Myocardial Revascularisation of the European Society of Cardiology (ESC).
MGuard™ is currently being investigated in the multi-centre international MASTER (MGuard™ for Acute ST Elevation Reperfusion) trial. This study has been designed to evaluate the MGuard™ stent compared to commercially-approved BMS or DES products in STEMI patients undergoing primary angioplasty. The trial is fully enrolled and preliminary top line results are expected in the third quarter of 2012. Plans for a registration study in the US are also at an advanced stage.